Literature DB >> 8535194

A retrospective analysis of treatment outcome in 106 cases of localized gastric non-Hodgkin lymphomas. Danish Lymphoma Study Group, LYFO.

H Brincker1, F D'Amore.   

Abstract

197 cases of gastric lymphoma were reported to a population-based Danish registry of non-Hodgkin's lymphomas. 106 of these cases were localized, representing stages IE and II1E, and were analyzed retrospectively, using Cox regression analysis. 67 had surgical resection, 51 chemotherapy, and 55 radiotherapy, or combinations thereof. No type of treatment showed any superiority as regards survival (p = 0.13). Overall 5-year survival was 67%. The pretherapeutic presence of fever or S-LDH-elevation had a far more significant influence on survival than histology or any of the treatments or treatment combinations. Surgical resection was associated with a significantly higher risk of late complications than radiotherapy, suggesting that radiotherapy may be preferable to surgery as the primary treatment in localized gastric lymphoma. It could not be determined from the available data whether the addition of chemotherapy to the primary treatment provides any survival benefit.

Entities:  

Mesh:

Year:  1995        PMID: 8535194     DOI: 10.3109/10428199509059619

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

Review 1.  The diminishing role of surgery in the treatment of gastric lymphoma.

Authors:  Sam S Yoon; Daniel G Coit; Carol S Portlock; Martin S Karpeh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 2.  Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.

Authors:  Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

3.  Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.

Authors:  Fatih Selçukbiricik; Deniz Tural; Olgun Elicin; Selin Berk; Mustafa Ozgüroğlu; Nuran Bese; Burhan Ferhanoglu
Journal:  ISRN Oncol       Date:  2012-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.